Skip to main content

RTW Investments, LP

13F filer · CIK 0001493215
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$11.7BU.S. long equity reported on 13F
Positions849 new · 13 closed
Net flow last quarter-$82MBuys minus sells
Top 10 positions weight47.7%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202684 positions
MDGLMadrigal Pharmaceuticals, Inc.$1.07B9.14%8.63%Not reportedQ2 2023
ARGXArgenx SE$658M5.62%1.15%Not reportedQ2 2017
PTCTPTC Therapeutics, Inc.$632M5.39%9.30%Not reportedQ4 2016
PTGXProtagonist Therapeutics, Inc$620M5.30%7.83%0.0%Q3 2019
CGONCG Oncology, Inc.$605M5.16%9.64%+21.9%Q1 2024
INSMINSMED Inc$516M4.41%2.22%Not reportedQ2 2023
TNGXTango Therapeutics, Inc.$435M3.71%8.26%+4.5%Q3 2021
SYRESpyre Therapeutics, Inc.$377M3.22%4.83%+1.9%Q4 2023
CELCCelcuity Inc.$346M2.95%6.76%+8.7%Q4 2025
ERASErasca, Inc.$329M2.81%5.74%+11.1%Q4 2025
RDNTRadNet, Inc.$299M2.55%6.16%+13.1%Q4 2023
ORKAOruka Therapeutics, Inc.$299M2.55%5.14%+52.5%Q3 2024
NTRANatera, Inc.$271M2.32%0.70%-20.0%Q3 2015
RAREUltragenyx Pharmaceutical Inc.$260M2.22%7.91%+113.7%Q4 2021
IRTCiRhythm Holdings, Inc.$260M2.22%6.63%+30.8%Q4 2025
CYTKCytokinetics Inc$244M2.08%2.30%+5.2%Q3 2020
KLRAKailera Therapeutics, Inc.$237M2.03%8.31%NewQ2 2026
ESTAEstablishment Labs Holdings Inc.$228M1.95%8.91%Not reportedQ3 2018
GHGuardant Health, Inc.$222M1.90%1.11%Not reportedQ3 2020
NBIXNeurocrine Biosciences Inc$214M1.82%1.25%+19.4%Q2 2025
TARSTarsus Pharmaceuticals, Inc.$211M1.80%7.76%+0.3%Q4 2020
STOKStoke Therapeutics, Inc.$184M1.57%9.01%Not reportedQ2 2019
QUREuniQure N.V.$182M1.55%5.68%+52.4%Q4 2017
ACADAcadia Pharmaceuticals Inc$181M1.54%4.15%Not reportedQ2 2022
RGENRepligen Corp$169M1.45%2.20%+2.9%Q4 2025
URGNUroGen Pharma Ltd.$167M1.43%9.30%Not reportedQ3 2021
GHRSGH Research PLC$160M1.36%9.57%Not reportedQ2 2021
IMCRImmunocore Holdings plc$155M1.32%9.46%Not reportedQ1 2021
CMPSCOMPASS Pathways plc$151M1.29%7.88%+0.7%Q4 2024
IMTXImmatics N.V.$131M1.12%9.66%+0.6%Q3 2020
ZLABZai Lab Ltd$125M1.07%0.59%Not reportedQ4 2024
IMVTImmunovant, Inc.$122M1.05%1.54%Not reportedQ4 2019
BLTEBelite Bio, Inc$110M0.94%1.82%Not reportedQ3 2025
XNCRXencor Inc$109M0.93%9.12%Not reportedQ3 2024
TSHATaysha Gene Therapies, Inc.$92.3M0.79%4.17%-0.9%Q3 2023
COGTCogent Biosciences, Inc.$89.4M0.76%1.35%-57.7%Q3 2025
ALKSAlkermes plc.$87.6M0.75%1.00%Not reportedQ3 2023
GPCRStructure Therapeutics Inc.$86.3M0.74%0.75%Not reportedQ2 2024
REPLReplimune Group, Inc.$82M0.70%8.83%+0.7%Q2 2024
CSTLCastle Biosciences Inc$66.3M0.57%9.11%+0.7%Q3 2019
CADLCandel Therapeutics, Inc.$66.1M0.56%8.44%Not reportedQ1 2026
RCKTRocket Pharmaceuticals, Inc.$60.5M0.52%16.15%Not reportedQ1 2018
KODKodiak Sciences Inc.$58M0.49%2.37%Not reportedQ4 2025
AKTSAktis Oncology, Inc.$51.3M0.44%2.98%Not reportedQ1 2026
AXGNAxogen, Inc.$46.7M0.40%1.89%NewQ2 2026
DHRDanaher Corp$43.8M0.37%0.03%Not reportedQ4 2023
CGEMCullinan Therapeutics, Inc.$43.1M0.37%3.67%+38.6%Q2 2024
NGNENeurogene Inc.$42.8M0.37%8.61%Not reportedQ1 2024
HNGEHinge Health, Inc.$41.5M0.35%3.05%-74.1%Q4 2025
OBIOOrchestra BioMed Holdings, Inc.$41.2M0.35%15.90%+15.1%Q1 2023
Q1 2026Reported May 15, 202688 positions
MDGLMadrigal Pharmaceuticals, Inc.$1.04B10.38%8.65%Not reportedQ2 2023
INSMINSMED Inc$792M7.88%2.24%0.0%Q2 2023
PTGXProtagonist Therapeutics, Inc$533M5.31%7.88%Not reportedQ3 2019
PTCTPTC Therapeutics, Inc.$528M5.25%9.35%Not reportedQ4 2016
ARGXArgenx SE$518M5.16%1.15%+5.3%Q2 2017
CGONCG Oncology, Inc.$473M4.70%7.94%+247.1%Q1 2024
CELCCelcuity Inc.$347M3.45%6.29%+452.5%Q4 2025
TNGXTango Therapeutics, Inc.$278M2.77%9.23%+791.9%Q3 2021
ERASErasca, Inc.$261M2.60%5.20%+10917.4%Q4 2025
NTRANatera, Inc.$250M2.49%0.88%-16.7%Q3 2015
RDNTRadNet, Inc.$239M2.38%5.46%+8.8%Q4 2023
TARSTarsus Pharmaceuticals, Inc.$235M2.34%7.78%+0.3%Q4 2020
APGEApogee Therapeutics, Inc.$234M2.33%3.72%+2.6%Q3 2023
SYRESpyre Therapeutics, Inc.$210M2.09%5.29%Not reportedQ4 2023
COGTCogent Biosciences, Inc.$210M2.09%3.20%-28.1%Q3 2025
IRTCiRhythm Holdings, Inc.$197M1.96%5.08%+41.2%Q4 2025
STOKStoke Therapeutics, Inc.$183M1.82%9.04%+1.4%Q2 2019
CYTKCytokinetics Inc$179M1.78%2.21%Not reportedQ3 2020
ACADAcadia Pharmaceuticals Inc$159M1.58%4.18%Not reportedQ2 2022
ESTAEstablishment Labs Holdings Inc.$151M1.50%9.04%+2.6%Q3 2018
APLSApellis Pharmaceuticals, Inc.$148M1.48%2.88%-51.9%Q4 2021
IMCRImmunocore Holdings plc$147M1.46%9.58%Not reportedQ1 2021
RGENRepligen Corp$142M1.41%2.14%+13.4%Q4 2025
NBIXNeurocrine Biosciences Inc$140M1.39%1.06%Not reportedQ2 2025
GHGuardant Health, Inc.$137M1.36%1.13%Not reportedQ3 2020
IMTXImmatics N.V.$127M1.26%9.60%+12.6%Q3 2020
ZLABZai Lab Ltd$124M1.23%0.59%-5.5%Q4 2024
BLTEBelite Bio, Inc$114M1.13%1.82%Not reportedQ3 2025
ISRGIntuitive Surgical Inc$101M1.01%0.06%+117.3%Q2 2023
ORKAOruka Therapeutics, Inc.$101M1.00%4.10%Not reportedQ3 2024
GHRSGH Research PLC$83.4M0.83%9.57%Not reportedQ2 2021
XNCRXencor Inc$81.7M0.81%9.15%Not reportedQ3 2024
URGNUroGen Pharma Ltd.$81.7M0.81%9.33%Not reportedQ3 2021
CNTACentessa Pharmaceuticals PLC$81.6M0.81%1.33%+14.7%Q3 2024
IMVTImmunovant, Inc.$78.9M0.79%1.56%0.0%Q4 2019
RAREUltragenyx Pharmaceutical Inc.$76.4M0.76%3.71%+21.6%Q4 2021
HNGEHinge Health, Inc.$74.4M0.74%11.78%+446.0%Q4 2025
CSTLCastle Biosciences Inc$67.7M0.67%9.10%+30.4%Q3 2019
RCKTRocket Pharmaceuticals, Inc.$63.3M0.63%16.21%Not reportedQ1 2018
TSHATaysha Gene Therapies, Inc.$61.2M0.61%4.76%-16.6%Q3 2023
ALKSAlkermes plc.$59.1M0.59%1.00%Not reportedQ3 2023
CMPSCOMPASS Pathways plc$58.8M0.59%7.88%+21.4%Q4 2024
KODKodiak Sciences Inc.$56.7M0.56%2.39%0.0%Q4 2025
REPLReplimune Group, Inc.$56.3M0.56%8.89%+3.0%Q2 2024
CRNXCrinetics Pharmaceuticals, Inc.$52.7M0.52%1.38%+7.4%Q2 2025
QUREuniQure N.V.$42.3M0.42%4.10%-30.3%Q4 2017
WAYWaystar Holding Corp.$39.3M0.39%0.85%NewQ1 2026
ARWRArrowhead Pharmaceuticals, Inc.$36.7M0.37%0.42%+0.2%Q4 2014
OBIOOrchestra BioMed Holdings, Inc.$35.3M0.35%14.17%Not reportedQ1 2023
VSTMVerastem, Inc.$34.9M0.35%7.49%Not reportedQ1 2025
Q4 2025Reported Feb 17, 202690 positions
MDGLMadrigal Pharmaceuticals, Inc.$1.16B11.63%8.73%Not reportedQ2 2023
INSMINSMED Inc$843M8.44%2.26%+57.0%Q2 2023
PTCTPTC Therapeutics, Inc.$588M5.89%9.51%Not reportedQ4 2016
ARGXArgenx SE$566M5.67%1.09%Not reportedQ2 2017
PTGXProtagonist Therapeutics, Inc$442M4.43%8.08%-12.1%Q3 2019
NTRANatera, Inc.$344M3.44%1.07%-25.0%Q3 2015
RDNTRadNet, Inc.$281M2.81%5.09%+39.9%Q4 2023
TARSTarsus Pharmaceuticals, Inc.$273M2.74%7.84%+5.0%Q4 2020
COGTCogent Biosciences, Inc.$270M2.70%4.72%+119.0%Q3 2025
PENPenumbra Inc$269M2.70%2.21%Not reportedQ4 2020
IRTCiRhythm Holdings, Inc.$210M2.10%3.66%NewQ4 2025
APGEApogee Therapeutics, Inc.$205M2.05%3.97%Not reportedQ3 2023
APLSApellis Pharmaceuticals, Inc.$193M1.93%6.05%Not reportedQ4 2021
ACADAcadia Pharmaceuticals Inc$191M1.91%4.20%Not reportedQ2 2022
ESTAEstablishment Labs Holdings Inc.$189M1.89%8.83%Not reportedQ3 2018
STOKStoke Therapeutics, Inc.$176M1.76%9.41%+8.3%Q2 2019
RGENRepligen Corp$174M1.75%1.89%NewQ4 2025
CYTKCytokinetics Inc$173M1.73%2.21%Not reportedQ3 2020
IMCRImmunocore Holdings plc$169M1.69%9.61%Not reportedQ1 2021
AXSMAxsome Therapeutics, Inc.$162M1.62%1.75%-20.6%Q1 2019
GHGuardant Health, Inc.$151M1.52%1.13%Not reportedQ3 2020
NBIXNeurocrine Biosciences Inc$151M1.51%1.06%Not reportedQ2 2025
SYRESpyre Therapeutics, Inc.$137M1.37%5.34%+15.2%Q4 2023
ZLABZai Lab Ltd$123M1.23%0.63%+203.7%Q4 2024
IMTXImmatics N.V.$120M1.20%8.53%+29.7%Q3 2020
BLTEBelite Bio, Inc$114M1.15%1.82%+128.9%Q3 2025
URGNUroGen Pharma Ltd.$106M1.07%9.40%Not reportedQ3 2021
XNCRXencor Inc$104M1.04%9.43%+8.9%Q3 2024
PODDInsulet Corp$92.3M0.92%0.46%Not reportedQ2 2017
TSHATaysha Gene Therapies, Inc.$90.2M0.90%5.75%-32.7%Q3 2023
MASIMasimo Corp$88.9M0.89%1.27%Not reportedQ3 2015
QUREuniQure N.V.$88.8M0.89%5.95%-16.1%Q4 2017
SYKStryker Corp$86.1M0.86%0.06%-50.0%Q3 2023
CGONCG Oncology, Inc.$83.5M0.84%2.49%+18.3%Q1 2024
CSTLCastle Biosciences Inc$82.3M0.82%7.13%Not reportedQ3 2019
IMVTImmunovant, Inc.$80.8M0.81%1.56%Not reportedQ4 2019
BBNXBeta Bionics, Inc.$76.2M0.76%5.64%-24.2%Q1 2025
GHRSGH Research PLC$75.4M0.75%9.57%+6.5%Q2 2021
REPLReplimune Group, Inc.$69.4M0.70%8.97%+11.6%Q2 2024
RAREUltragenyx Pharmaceutical Inc.$69M0.69%3.11%-7.9%Q4 2021
CRNXCrinetics Pharmaceuticals, Inc.$62.9M0.63%1.41%+54.9%Q2 2025
ORKAOruka Therapeutics, Inc.$62.4M0.62%4.22%+5.8%Q3 2024
RCKTRocket Pharmaceuticals, Inc.$62.1M0.62%16.33%Not reportedQ1 2018
CMPSCOMPASS Pathways plc$60.4M0.61%9.11%+0.6%Q4 2024
ISRGIntuitive Surgical Inc$57.3M0.57%0.03%-50.0%Q2 2023
RAPTRAPT Therapeutics, Inc.$55.5M0.56%5.91%+11.3%Q4 2024
CELCCelcuity Inc.$54.9M0.55%1.14%NewQ4 2025
VSTMVerastem, Inc.$50.8M0.51%8.46%+21.2%Q1 2025
ALKSAlkermes plc.$46.8M0.47%1.01%Not reportedQ3 2023
CNTACentessa Pharmaceuticals PLC$44.8M0.45%1.20%-21.9%Q3 2024
Q3 2025Reported Nov 14, 202574 positions
MDGLMadrigal Pharmaceuticals, Inc.$914M11.27%8.78%Not reportedQ2 2023
ARGXArgenx SE$497M6.12%1.11%Not reportedQ2 2017
RNAMAvidity Biosciences, Inc.$496M6.11%7.75%+18.2%Q2 2020
PTCTPTC Therapeutics, Inc.$475M5.86%9.69%Not reportedQ4 2016
INSMINSMED Inc$444M5.47%1.45%Not reportedQ2 2023
PTGXProtagonist Therapeutics, Inc$382M4.71%9.22%Not reportedQ3 2019
NTRANatera, Inc.$322M3.97%1.45%-22.9%Q3 2015
AKROAkero Therapeutics, Inc.$260M3.20%6.83%Not reportedQ4 2023
QUREuniQure N.V.$258M3.18%7.12%-14.2%Q4 2017
PENPenumbra Inc$220M2.70%2.22%+0.3%Q4 2020
RDNTRadNet, Inc.$215M2.64%3.66%+4.7%Q4 2023
MRUSMerus N.V.$191M2.35%2.67%-49.4%Q4 2021
TARSTarsus Pharmaceuticals, Inc.$189M2.33%7.49%+2.1%Q4 2020
SYKStryker Corp$181M2.23%0.13%-17.0%Q3 2023
IMCRImmunocore Holdings plc$177M2.18%9.65%Not reportedQ1 2021
ACADAcadia Pharmaceuticals Inc$152M1.88%4.22%-20.6%Q2 2022
CYTKCytokinetics Inc$150M1.84%2.27%Not reportedQ3 2020
NBIXNeurocrine Biosciences Inc$149M1.84%1.07%Not reportedQ2 2025
AXSMAxsome Therapeutics, Inc.$136M1.67%2.22%-26.2%Q1 2019
STOKStoke Therapeutics, Inc.$120M1.48%9.30%Not reportedQ2 2019
APGEApogee Therapeutics, Inc.$108M1.33%4.57%Not reportedQ3 2023
ESTAEstablishment Labs Holdings Inc.$106M1.31%8.91%+0.2%Q3 2018
MASIMasimo Corp$101M1.24%1.27%Not reportedQ3 2015
RAREUltragenyx Pharmaceutical Inc.$98M1.21%3.38%+90.8%Q4 2021
GHGuardant Health, Inc.$92.5M1.14%1.18%+72.9%Q3 2020
URGNUroGen Pharma Ltd.$90.7M1.12%9.71%Not reportedQ3 2021
ISRGIntuitive Surgical Inc$90.5M1.12%0.06%Not reportedQ2 2023
GHRSGH Research PLC$79.6M0.98%10.70%+0.5%Q2 2021
TSHATaysha Gene Therapies, Inc.$79.6M0.98%8.89%-2.7%Q3 2023
ZLABZai Lab Ltd$77.7M0.96%0.21%-58.6%Q4 2024
IMTXImmatics N.V.$75.1M0.93%7.25%+26.5%Q3 2020
XNCRXencor Inc$73M0.90%8.72%+158.9%Q3 2024
CGONCG Oncology, Inc.$68.5M0.84%2.17%Not reportedQ1 2024
BBNXBeta Bionics, Inc.$65.6M0.81%7.50%Not reportedQ1 2025
SYRESpyre Therapeutics, Inc.$60.7M0.75%5.99%Not reportedQ4 2023
RCKTRocket Pharmaceuticals, Inc.$57.7M0.71%16.35%Not reportedQ1 2018
CNTACentessa Pharmaceuticals PLC$55.6M0.68%1.70%+49.8%Q3 2024
ALKSAlkermes plc.$50.2M0.62%1.01%-64.3%Q3 2023
CMPSCOMPASS Pathways plc$49.9M0.61%9.07%+5.9%Q4 2024
COGTCogent Biosciences, Inc.$49.8M0.61%2.48%NewQ3 2025
VSTMVerastem, Inc.$47.9M0.59%8.13%+27.6%Q1 2025
DGXQuest Diagnostics Inc$47.6M0.59%0.22%-50.0%Q1 2025
LENZLENZ Therapeutics, Inc.$40.2M0.50%3.02%Not reportedQ1 2024
RAPTRAPT Therapeutics, Inc.$37.9M0.47%8.89%Not reportedQ4 2024
ORKAOruka Therapeutics, Inc.$37.4M0.46%4.02%Not reportedQ3 2024
DYNDyne Therapeutics, Inc.$36.6M0.45%2.03%+71.0%Q1 2024
CRNXCrinetics Pharmaceuticals, Inc.$36.3M0.45%0.92%+86.8%Q2 2025
AQSTAquestive Therapeutics, Inc.$34.9M0.43%5.14%NewQ3 2025
ABVXAbivax S.A.$29.7M0.37%0.55%NewQ3 2025
GEHCGE HealthCare Technologies Inc.$29.6M0.36%0.09%-37.1%Q1 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.